Cancer Research Group, Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain.
Nat Rev Clin Oncol. 2023 Apr;20(4):250-264. doi: 10.1038/s41571-023-00734-5. Epub 2023 Feb 20.
Cachexia is a devastating, multifactorial and often irreversible systemic syndrome characterized by substantial weight loss (mainly of skeletal muscle and adipose tissue) that occurs in around 50-80% of patients with cancer. Although this condition mainly affects skeletal muscle (which accounts for approximately 40% of total body weight), cachexia is a multi-organ syndrome that also involves white and brown adipose tissue, and organs including the bones, brain, liver, gut and heart. Notably, cachexia accounts for up to 20% of cancer-related deaths. Cancer-associated cachexia is invariably associated with systemic inflammation, anorexia and increased energy expenditure. Understanding these mechanisms is essential, and the progress achieved in this area over the past decade could help to develop new therapeutic approaches. In this Review, we examine the currently available evidence on the roles of both the tumour macroenvironment and microenvironment in cancer-associated cachexia, and provide an overview of the novel therapeutic strategies developed to manage this syndrome.
恶病质是一种破坏性的、多因素的、常不可逆的全身综合征,其特征是大量体重减轻(主要是骨骼肌和脂肪组织),约 50-80%的癌症患者会发生这种情况。尽管这种情况主要影响骨骼肌(占人体总重量的约 40%),但恶病质是一种多器官综合征,还涉及白色和棕色脂肪组织,以及包括骨骼、大脑、肝脏、肠道和心脏在内的器官。值得注意的是,恶病质导致的死亡约占癌症相关死亡的 20%。癌症相关恶病质总是与全身炎症、厌食和能量消耗增加有关。了解这些机制至关重要,过去十年在这一领域取得的进展可能有助于开发新的治疗方法。在这篇综述中,我们检查了肿瘤宏观环境和微环境在癌症相关恶病质中的作用的现有证据,并概述了为治疗这种综合征而开发的新的治疗策略。